**Trader consensus around an 82% chance that no new COVID variant of concern will be declared before 2027 stems from the continued dominance of Omicron-descendant lineages without the emergence of a genetically distant or higher-risk strain.** As of September 2026, WHO tracks JN.1 as the sole variant of interest and lists XFG, NB.1.8.1, BA.3.2, and PQ.16.1.1 as variants under monitoring; these show incremental spike mutations and some immune escape but no consistent evidence of greater transmissibility, severity, or public-health impact compared with prior Omicron waves. Global test positivity and hospitalizations remain low relative to earlier years, supported by widespread population immunity from vaccination and prior infection plus improved clinical management. Recent shifts, such as XFG rising then stabilizing or BA.3.2 increasing modestly in sequenced samples without driving excess burden, align with gradual within-lineage evolution rather than the saltation events that previously triggered new designations. Vaccine updates for the 2026–27 season targeting XFG further illustrate adaptation within the existing framework. While gaps in genomic surveillance introduce uncertainty, the pattern through mid-2026 supports the market’s assessment that a qualifying new variant of concern is unlikely in the remaining months before 2027.